Clinical and Economic Utility of BTK Inhibitors in CLL

home / peer-exchange / clinical-and-economic-utility-of-btk-inhibitors-in-cll

A panel of experts discuss chronic lymphocytic leukemia, focusing on the integration of Bruton tyrosine kinase inhibitors into the treatment landscape, the economic and access considerations of BTK inhibitor therapy, and future directions and ongoing research opportunities in the management of CLL.

Episodes

A panel of 4 experts on CLL

June 28th 2024EP. 1: Recent Trends and Innovations in the Management of CLL

Ryan Haumschild, PharmD, MS, MBA;Roy Beveridge, MD;Brian T. Hill, MD, PhD;Adam S. Kittai, MD

Experts on the treatment of chronic lymphocytic leukemia discuss recent trends and innovations in the therapeutic landscape.

A panel of 4 experts on CLL

June 28th 2024EP. 2: CLL Treatment Landscape: Overview of BTK Inhibitors

Ryan Haumschild, PharmD, MS, MBA;Roy Beveridge, MD;Brian T. Hill, MD, PhD;Adam S. Kittai, MD

A panel of experts provide an overview of BTK inhibitors for the treatment of patients with chronic lymphocytic leukemia.

A panel of 4 experts on CLL

July 12th 2024EP. 3: Evaluating Value of BTK Inhibitors in CLL Treatment

Ryan Haumschild, PharmD, MS, MBA;Roy Beveridge, MD;Brian T. Hill, MD, PhD;Adam S. Kittai, MD

Experts evaluate the value of BTK inhibitors in CLL treatment.

A panel of 4 experts on CLL

July 12th 2024EP. 4: Factors Influencing Choice of Second-Generation BTKi Monotherapy

Ryan Haumschild, PharmD, MS, MBA;Roy Beveridge, MD;Brian T. Hill, MD, PhD;Adam S. Kittai, MD

Specialists discuss factors influencing the choices of second-generation BTK monotherapy.

A panel of 4 experts on CLL

July 23rd 2024EP. 5: Empowering Patients: Key Considerations for BTK Inhibitor Adherence

Ryan Haumschild, PharmD, MS, MBA;Roy Beveridge, MD;Brian T. Hill, MD, PhD;Adam S. Kittai, MD

A conversation on how to empower patients and the considerations for BTK inhibitor adherence.

A panel of 4 experts on CLL

July 23rd 2024EP. 6: Optimizing Therapy Sequencing in CLL

Ryan Haumschild, PharmD, MS, MBA;Roy Beveridge, MD;Brian T. Hill, MD, PhD;Adam S. Kittai, MD

A panel of experts discuss optimizing therapy sequencing in CLL.

A panel of 4 experts on CLL

July 29th 2024EP. 7: Leveraging MAICs for Decision-Making in CLL BTK Inhibitor Selection

Ryan Haumschild, PharmD, MS, MBA;Roy Beveridge, MD;Brian T. Hill, MD, PhD;Adam S. Kittai, MD

Experts discuss leveraging MAICs for decision-making when choosing a CLL BTK inhibitor.

A panel of 4 experts on CLL

July 29th 2024EP. 8: Decision-Making in CLL: The Role of Real-World Evidence

Ryan Haumschild, PharmD, MS, MBA;Roy Beveridge, MD;Brian T. Hill, MD, PhD;Adam S. Kittai, MD

A discussion on therapeutic decision-making in CLL and the role of real-world evidence.

A panel of 4 experts on CLL

August 5th 2024EP. 9: Combination Regimens with BTK Inhibitors: New Frontiers in CLL Treatment

Ryan Haumschild, PharmD, MS, MBA;Roy Beveridge, MD;Brian T. Hill, MD, PhD;Adam S. Kittai, MD

A panel of experts discuss combination regimens with BTK inhibitors.

A panel of 4 experts on CLL

August 5th 2024EP. 10: Financial Challenges of BTK Inhibitor Therapy in CLL: Impact on Access and Utilization

Ryan Haumschild, PharmD, MS, MBA;Roy Beveridge, MD;Brian T. Hill, MD, PhD;Adam S. Kittai, MD

Experts discuss financial challenges of BTK inhibitor therapy.

A panel of 4 experts on CLL

August 12th 2024EP. 11: Navigating Access Challenges in CLL Treatment: Strategies for Overcoming Barriers 

Ryan Haumschild, PharmD, MS, MBA;Roy Beveridge, MD;Brian T. Hill, MD, PhD;Adam S. Kittai, MD

A panel of experts discuss navigating access challenges in CLL treatment.

A panel of 4 experts on CLL

August 12th 2024EP. 12: The Inflation Reduction Act: Implications for Patient Access in CL

Ryan Haumschild, PharmD, MS, MBA;Roy Beveridge, MD;Brian T. Hill, MD, PhD;Adam S. Kittai, MD

A group of experts discuss implications for patient access in CLL.

A panel of 4 experts on CLL

August 19th 2024EP. 13: Patient Access Advocacy for BTK Inhibitors

Ryan Haumschild, PharmD, MS, MBA, CPEL;Roy Beveridge, MD;Brian T. Hill, MD, PhD;Adam S. Kittai, MD

A panel of specialists discuss patient access advocacy for BTK inhibitors.

A panel of 4 experts on CLL

August 19th 2024EP. 14: Future Directions of BTK Inhibitors in Leukemia and Lymphoma

Ryan Haumschild, PharmD, MS, MBA, CPEL;Roy Beveridge, MD;Brian T. Hill, MD, PhD;Adam S. Kittai, MD

Experts discuss future directions of BTK inhibitors.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions